Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Clin Cancer Res. 2018 Aug 6;24(23):5883–5894. doi: 10.1158/1078-0432.CCR-17-3668

Fig 2.

Fig 2.

(A) Proportions of low- and high-delta tumors in patients with co-occurring mutations, including KRAS & TP53, KRAS & PIK3CA, or KRAS & SMAD4 (Fisher’s exact test, P=0.01). (B) Next generation sequencing data of 15 patient derived xenografts, classified according to the delta on baseline CT. High delta PDAC were more likely to harbor mutations in both KRAS and TP53 than low delta PDAC (P=0.04).